Telazorlimab, initially known as GBR 830, was the first antibody targeting OX40 that was evaluated in a phase 2a trial, where its efficacy, safety, and adverse effects were investigated in patients with AD (atopic dermatitis) [8]. This evidence concerns the gene TNFRSF4 and atopic eczema.